ARCHIVES

FDA Reaction to DCT Proposals ‘Positive,’ But Chabner, Wittes ‘Disappointed’ In That Response

This article is from The Cancer Letter archive.

Vol. 14 No. 25 | June 17, 1988

Download PDF Visit The Full Archive

Related Articles

Letter to the Editor: Colleagues describe Bunn As Leader, Patient Advocate

January 12, 1996

Huebner Retires, Named Scientist Emeritus

November 19, 1982

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

March 28, 2014

Advocacy: Journal Club Leader Sought By NBCC

August 22, 1997

MRI Reveals Information That May Alter Treatment

December 28, 2007

Clinical Trials Issues: Maryland Law Mandates Insurance Coverage Of Patient Care Costs In Clinical Trials

July 3, 1998